You are here: Industry Insights > Glenmark

News List

Glenmark partners Harbour BioMed to develop oncology candidate in China drugs
August 08, 2018
Glenmark Pharmaceuticals has signed an exclusive licence agreement with Harbour BioMed for the development, manufacture and commercialisation of its immuno-oncology candidate GBR 1302 in Greater China to treat HER2-positive cancers.
Glenmark signs licence deal with Harbour BioMed biospectrumasia
August 08, 2018
Exclusive license agreement potentially worth more than $120 million in addition to royalties
Glenmark announces study supporting biosimilarity criteria for GBR 310 compared to the reference product Omalizumab expressbpd
July 27, 2018
Glenmark is seeking use of GBR 310 for the same indications as the reference biologic for the treatment of allergic asthma and chronic idiopathic urticaria (CIU)
Glenmark Announces Licensing Agreement with Seqirus americanpharmaceuticalreview
July 11, 2018
Glenmark Pharmaceuticals announced its subsidiary Glenmark Specialty has entered into an exclusive licensing agreement with Seqirus to commercialize Ryaltris in Australia and New Zealand.
Glenmark to commercialise Ryaltris in Australia, NZ biospectrumasia
July 09, 2018
Glenmark will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.
Glenmark recalls over 1 lakh bottles of anti-inflammatory drug in US expressbpd
April 09, 2018
Glenmark Pharmaceuticals is recalling over one lakh bottles of anti-inflammatory Indomethacin capsules from the US market due to incorrect instructions on the labelling, latest Enforcement report of the US regulator has said.
Glenmark expects 80 per cent sales by 2021 expressbpd
January 11, 2018
Glenmark Pharmaceuticals is expecting the US, Indian and European markets, along with active pharmaceutical ingredient (API) segment, to contribute over 80 per cent of its sales by 2021
Glenmark receives US FDA approval for HAILEYTM 24 Fe 1 mg/ 20 mcg expressbpd
November 21, 2017
Glenmark’s current portfolio consists of 128 products authorised for distribution in the US marketplace and 59 ANDA’s pending approval with the US FDA.
Glenmark launches Kwitz expressbpd
November 17, 2017
Glenmark Pharmaceuticals announced the launch of Kwitz, a medically approved nicotine replacement therapy that helps smokers embark on a step by step journey towards a smoke-free life.
Glenmark launches oral drug for psoriasis treatment expressbpd
October 25, 2017
Glenmark Pharmaceuticals has launched Apremilast, the first advanced oral systemic treatment for psoriasis in India.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page